Publication | Closed Access

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

Hematological MalignancyBone Marrow FailureOral DeferasiroxSingle ArmMulti-center TrialHematologyPharmacotherapyMedicineMyeloid Neoplasia